Free Market Capitalist fave Jazz Pharmaceuticals (JAZZ) takes over Dublin-based Azur Pharma Ltd. in a deal to add a pain drug, Prialt , and diversify it's product portfolio. Jazz Pharmaceuticals (JAZZ) fell $2.03 to $41.70 in the after-hours session. I would use the pullback on this news as a buying opportunity. Jazz (JAZZ) delivered a stellar quarter and this deal will only add to their sales growth and bottom line.
This is not a recommendation to buy or sell any securities. DAK had no position in any of the stocks mentioned at time of publication but positions can change at anytime.
No comments:
Post a Comment